Related Experiment Video

Updated: Mar 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies

Kari L Ring1, Janelle Pakish, Amir A Jazaeri

  • 1From the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.K.L.R. and J.P. contributed equally to the current review.

Cancer Journal (Sudbury, Mass.)
|April 26, 2016
PubMed

Insights

Immune checkpoint inhibitors show promise for gynecologic cancers like ovarian, endometrial, and cervix cancer. Further research is needed to identify which patients benefit and optimize treatment strategies for these malignancies.

Area of Science:

  • Gynecologic Oncology
  • Immunotherapy
  • Cancer Treatment

Background:

  • The immune system significantly influences gynecologic malignancies.
  • Immune checkpoint inhibitors (ICIs) demonstrate preliminary efficacy in ovarian, endometrial, and cervical cancers.

Purpose of the Study:

  • To review completed and ongoing clinical trials of immune checkpoint blockade in gynecologic malignancies.
  • To address unanswered questions regarding patient selection and optimal integration of ICIs into treatment paradigms.

Main Methods:

  • Comprehensive review of completed clinical trials.
  • Analysis of ongoing clinical trials across different gynecologic cancer sites.
  • Examination of emerging preclinical and clinical data on predictive markers.

Main Results:

  • Completed trials of immune checkpoint blockade in gynecologic malignancies have been outlined.
  • Ongoing trials are actively investigating ICI efficacy in ovarian, endometrial, and cervical cancers.
  • Key questions regarding patient benefit and treatment timing remain largely unresolved.

Conclusions:

  • Immune checkpoint inhibitors represent an emerging therapeutic field for gynecologic malignancies.
  • Identifying predictive markers for response and resistance is crucial.
  • Developing rational combination strategies will advance ICI use in treating these cancers.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K